darolutamide (Nubeqa)
Jump to navigation
Jump to search
Indications
- nonmetastatic, castration-resistant prostate cancer
Dosage
Adverse effects
- most common
- other
- ischemic heart disease (4.3%)
- heart failure (2.1%)
Clinical trials
- reduces morality in castration-resistant prostate cancer
More general terms
References
- ↑ FDA Announcement. July 30, 2019 FDA approves darolutamide for non-metastatic castration- resistant prostate cancer. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-darolutamide-non-metastatic-castration-resistant-prostate-cancer
- ↑ Fizazi K et al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med 2020 Sep 10; 383:1040. PMID: https://www.ncbi.nlm.nih.gov/pubmed/32905676 https://www.nejm.org/doi/10.1056/NEJMoa2001342